Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's disease

References

• Rogers G, Davies D, Pink J, et al. Parkinson's disease: summary of updated NICE guidance. BMJ. 2017;358:j1951.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):774–386.
   Web of Science ®Google Scholar
• Dorsey ER, Sherer T, Okun MS, et al. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3–s8.
   PubMedGoogle Scholar
• Parkinson's UK. The incidence and prevalence of Parkinson's in the UK. Results from the Clinical Practice Research Datalink Summary Report; 2018.
   Google Scholar
• Weir S, Samnaliev M, Kuo TC, et al. Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK. Mov Disord. 2018;33(6):974–981.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–450.
   PubMed Web of Science ®Google Scholar
• Vijiaratnam N, Foltynie T. Therapeutic strategies to treat or prevent off episodes in adults with Parkinson's disease. Drugs. 2020;80(8):775–796.
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Poewe W, Brooks D. Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov Disord. 2018;33(6):909–919.
   PubMed Web of Science ®Google Scholar
• Rosqvist K, Horne M, Hagell P, et al. Levodopa effect and motor function in late stage Parkinson's disease. J Parkinsons Dis. 2018;8(1):59–70.
   PubMedGoogle Scholar
• Chandler C, Folse H, Gal P, et al. Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study. J Mark Access Health Policy. 2021;9(1):1922163.
   PubMedGoogle Scholar
• Woodrow H, Horne MK, Fernando CV, et al. A blinded, controlled trial of objective measurement in Parkinson's disease. NPJ Parkinsons Dis. 2020;6(1):35.
   PubMed Web of Science ®Google Scholar
• Meira-Machado L, de Uña-Alvarez J, Cadarso-Suárez C, et al. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18(2):195–222.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Parkinson’s disease in adults NICE guideline Published: 19 July 2017. Available at: www.nice.org.uk/guidance/ng71. 2017.
   Google Scholar
• Joshi R, Bronstein JM, Keener A, et al. PKG movement recording system use shows promise in routine clinical care of patients with Parkinson's disease. Front Neurol. 2019;10:1027.
   PubMed Web of Science ®Google Scholar
• Dams J, Klotsche J, Bornschein B, et al. Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. Health Qual Life Outcomes. 2013;11:35.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Internal clinical guideline. NICE Economic analysis.- Parkinson's Disease, Appendix F:Full Health Economics Report; 2016.
   Google Scholar
• Antonini A, Odin P, Pahwa R, et al. The Long-Term impact of levodopa/carbidopa intestinal gel on 'off'-time in patients with advanced Parkinson's disease: a systematic review. Adv Ther. 2021;38(6):2854–2890.
   PubMed Web of Science ®Google Scholar
• Holden SK, Finseth T, Sillau SH, et al. Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson's progression markers initiative cohort. Mov Disord Clin Pract. 2018;5(1):47–53.
   PubMed Web of Science ®Google Scholar
• Schrag A, Dodel R, Spottke A, et al. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord. 2007;22(7):938–945.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. National Life Tables. 2021.
   Google Scholar
• Xu J, Gong DD, Man CF, et al. Parkinson's disease and risk of mortality: meta-analysis and systematic review. Acta Neurol Scand. 2014;129(2):71–79.
   PubMed Web of Science ®Google Scholar
• NHS England. NHS England » National tariff payment system 2021. /22. Available from: https://www.england.nhs.uk/pay-syst/national-tariff/national-tariff-payment-system/.
   Google Scholar
• Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339–347.
   PubMed Web of Science ®Google Scholar
• Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–953.
   PubMed Web of Science ®Google Scholar
• Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol. 2010;67(1):64–70.
   PubMedGoogle Scholar
• O'Mahony T. Cost-Benefit analysis and the environment: the time horizon is of the essence. Environ Impact Assess Rev. 2021;89:106587.
   Web of Science ®Google Scholar
• Chen L, Cai G, Weng H, et al. More sensitive identification for bradykinesia compared to tremors in Parkinson's disease based on Parkinson's KinetiGraph (PKG). Front Aging Neurosci. 2020;12:594701.
   PubMed Web of Science ®Google Scholar
• Khodakarami H, Shokouhi N, Horne M. A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson's disease using an ambulatory monitor. J Neuroeng Rehabil. 2021;18(1):116.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Bergquist F, Horne M, et al. Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the personal KinetiGraph®). J Clin Mov Disord. 2020;7:5.
   PubMedGoogle Scholar
• Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16(1):495.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalized medicine in Parkinson's disease: time to be precise. Mov Disord. 2017;32(8):1147–1154.
   PubMed Web of Science ®Google Scholar
• Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284–2303.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos SS. Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. CNS Neurosci Ther. 2012;18(5):380–387.
   PubMed Web of Science ®Google Scholar